. 2017 Dec 6;32(1):72–85. doi: 10.1111/jvim.14885

Table 4.

Within‐group paired comparisons and between‐group unpaired comparisons of the change from baseline to day 35 of various quality of life and physical examination variables

Categorical Variables	Treatment Group	N	Deteriorated	Unchanged	Improved	Within‐Group Comparison (Wilcoxon Signed Ranks)	Between‐Group Comparison (Mann‐Whitney)
Appetite	Placebo	160	6	140	14	0.12	0.33
Appetite	Pimobendan	169	5	144	20	0.0012	0.33
Demeanor	Placebo	160	3	135	22	<0.0001	0.34
Demeanor	Pimobendan	169	2	138	29	<0.0001	0.34
Exercise tolerance	Placebo	160	4	132	24	<0.0001	0.75
Exercise tolerance	Pimobendan	169	3	144	22	<0.0001	0.75
Fainting	Placebo	160	2	157	1	1.0000	0.65
Fainting	Pimobendan	169	1	167	1	1.0000	0.65
Respiratory effort	Placebo	160	3	148	9	0.15	0.75
Respiratory effort	Pimobendan	169	1	162	6	0.13	0.75
Cough	Placebo	160	9	134	17	0.12	0.46
Cough	Pimobendan	169	6	143	20	0.0038	0.46
Nocturnal dyspnea or cough	Placebo	160	3	152	5	0.73	0.65
Nocturnal dyspnea or cough	Pimobendan	169	2	161	6	0.29	0.65
Body condition score	Placebo	160	24	123	13	0.070	0.55
Body condition score	Pimobendan	169	24	127	18	0.36	0.55
Heart failure stage	Placebo	160	–	157	3	0.25	0.76
Heart failure stage	Pimobendan	169	–	165	4	0.13	0.76

			Decreased	Unchanged	Increased
Auscultation (change in murmur grade)	Placebo	160	12	130	18	0.28	0.22
Auscultation (change in murmur grade)	Pimobendan	169	21	131	17	0.52	0.22

All P‐values that appear in bold are < 0.05.